Molecular Biology Reports

, Volume 39, Issue 9, pp 8749–8753

Lack of association between miR-149 C>T polymorphism and cancer susceptibility: a meta-analysis based on 4,677 cases and 4,830 controls


DOI: 10.1007/s11033-012-1735-4

Cite this article as:
Zhang, J., Liu, Y. & Gan, Y. Mol Biol Rep (2012) 39: 8749. doi:10.1007/s11033-012-1735-4


To derive a more precise estimation of the relationship between miR-149 C>T polymorphism and cancer risk, a meta-analysis was performed. A total of 8 studies including 4,677 cases and 4,830 controls were involved in this meta-analysis. Overall, no significantly elevated cancer risk was associated with miR-149 T allele when all studies were pooled into the meta-analysis (CT vs. CC: OR = 0.977, 95 % CI = 0.882–1.082; TT vs. CC: OR = 0.985, 95 % CI = 0.857–1.132; dominant model: OR = 0.984, 95 % CI = 0.893–1.084; recessive model: OR = 1.026, 95 % CI = 0.931–1.132). In the subgroup analysis by ethnicity or study design, no significantly increased risks were found under all models. When stratified by cancer type, there were no significant cancer risk changes for lung cancer, breast cancer or colorectal cancer when miR-149 T allele was included. In conclusion, this meta-analysis suggests that the miR-149 C>T polymorphism may not contribute to cancer susceptibility.


miR-149 Polymorphism Cancer Susceptibility 

Supplementary material

11033_2012_1735_MOESM1_ESM.jpg (229 kb)
Supplementary files. Figure 1 Forest plots for the association between miR-149 C/T (rs2292832) polymorphism and cancer risk. a CT vs. CC analysis. b TT vs. CC analysis. c dominant model analysis. d recessive model analysis. (JPEG 229 kb)

Copyright information

© Springer Science+Business Media B.V. 2012

Authors and Affiliations

  1. 1.Department of Medical Oncology, Cancer Hospital, Fudan UniversityFudan UniversityShanghaiChina
  2. 2.Department of Oncology, Shanghai Medical CollegeFudan UniversityShanghaiChina
  3. 3.Office of Clinical Research Administration, Cancer HospitalFudan UniversityShanghaiChina
  4. 4.Shanghai Cancer InstituteShanghai Jiao Tong University School of MedicineShanghaiChina

Personalised recommendations